Inconsistent approaches of the G-BA regarding acceptance of primary study endpoints as being relevant to patients - an analysis of three disease areas: oncological, metabolic, and infectious diseases [PDF]
Background Previous evaluations of oncological medicines in the German early benefit assessment (EBA) procedure have demonstrated inconsistent acceptance of endpoints by regulatory authorities and the Federal Joint Committee (G-BA).
Thomas Staab +3 more
doaj +3 more sources
Ba–Sr–V as Geogenic and Traffic Tracers in Paediatric Hair from Urban–Industrial Spain, with Co-Located Topsoil Vanadium [PDF]
Urban–industrial environments can generate mixed geogenic and traffic-related metal signatures in paediatric scalp hair, yet interpretation is challenged by left-censoring and limited health-based guidance values for hair.
Antonio Peña-Fernández +4 more
doaj +2 more sources
G-BA gestattet Ausdehnung der Untersuchungszeiträume U6-U9 [PDF]
Fricke A, Cornell S, Gerlof H.
europepmc +3 more sources
Ocular and Systemic Pharmacokinetics of Baicalein and Baicalin After Intravitreal Injection and Oral Administration in Mice [PDF]
Background: Glaucoma requires therapies that extend beyond intraocular pressure (IOP)-lowering strategies, and baicalein (BA) offers dual IOP-lowering and neuroprotective potential. This study evaluated the pharmacokinetics of BA and its major metabolite
Yunshi Zhi +5 more
doaj +2 more sources
[Potential consequences of the German hospital reform and the resolution of the Federal Joint Committee on the treatment of proximal femoral fractures for the Federal State of Saxony : Improvement or hazard for the quality of care?] [PDF]
Osterhoff G +4 more
europepmc +3 more sources
Key summary of German national guideline for adult patients with nosocomial pneumonia- Update 2024 Funding number at the Federal Joint Committee (G-BA): 01VSF22007. [PDF]
Rademacher J +26 more
europepmc +3 more sources
Arzneimitteltherapiesicherheit durch den G-BA
Kathrin Pieloth, Jana Heiler
openaire +2 more sources
Neugebauer: „Aus unserer Sicht innovationsfeindlich“
Am 27. Juli 2022 hat das Bundeskabinett den Entwurf eines Gesetzes zur finanziellen Stabilisierung der gesetzlichen Krankenversicherung (GKV-Finanzstabilisierungsgesetz) beschlossen, der – nachdem ins parlamentarische Verfahren eingebracht – am 20 ...
Peter Stegmaier
doaj +1 more source
Suche nach dem Versorgungsforschungs-Impact
Es ist eine reine Fleißaufgabe, sich der Frage zu nähern, wie viele der vom Innovationsfonds geförderten und inzwischen vom Innovationsausschuss mit Beschluss beendeten Versorgungsforschungsprojekte „positiv“ oder „negativ“ beschieden wurden, da der G-BA
Peter Stegmaier
doaj +1 more source

